FENNEC PHARMACEUTICALS INC. (FENC) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income $1.74M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$119.00K; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$189.00K; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$2.73M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | $1.74M | (m) | (m) | (m) | (m) | $50.00K* | (m) | $118.00K | (m) | $42.00K |
| 2026-03-31 | Reported | (m) | -$119.00K | (m) | (m) | (m) | (m) | $2.38M | (m) | $49.00K | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$189.00K | (m) | (m) | (m) | (m) | $1.49M* | (m) | $29.00K | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$2.73M | (m) | (m) | (m) | (m) | -$3.69M* | (m) | $107.00K | (m) | $0.00* |
| 2025-03-31 | Reported | (m) | -$808.00K | (m) | (m) | (m) | (m) | -$4.32M | (m) | $94.00K | (m) | $0.00 |
| 2024-09-30 | Reported | (m) | -$5.20M | (m) | (m) | (m) | (m) | -$2.21M* | (m) | $97.00K | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$5.04M | (m) | (m) | (m) | (m) | -$8.39M* | (m) | $157.00K | (m) | (m) |
| 2024-03-31 | Reported | (m) | $13.74M | (m) | (m) | (m) | (m) | $39.05M | (m) | $3.00K | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$1.02M | (m) | (m) | (m) | (m) | -$2.76M* | $331.00K | $12.00K | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$4.67M | (m) | (m) | (m) | (m) | -$3.95M* | $148.00K | $8.00K | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$5.27M | (m) | (m) | (m) | (m) | -$5.58M | $95.00K | $4.00K | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$7.90M | (m) | (m) | (m) | (m) | -$5.01M* | (m) | $846.00K | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$5.01M | (m) | (m) | (m) | (m) | -$3.39M | (m) | $1.13M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$3.55M | (m) | (m) | (m) | (m) | -$2.86M | (m) | $1.44M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$4.17M | (m) | (m) | (m) | (m) | -$2.96M | (m) | $1.24M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$3.92M | (m) | (m) | (m) | (m) | -$4.43M | (m) | $800.00K | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$4.92M | (m) | (m) | (m) | (m) | -$3.59M | (m) | $2.42M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$5.86M | (m) | (m) | (m) | (m) | -$5.45M | (m) | $1.37M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$4.84M | (m) | (m) | (m) | (m) | -$3.12M | (m) | $1.12M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$3.83M | (m) | (m) | (m) | (m) | -$3.75M | (m) | $1.39M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$1.86M | (m) | (m) | (m) | (m) | -$2.23M | (m) | $795.00K | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$4.81M | (m) | (m) | (m) | (m) | -$2.76M | (m) | $1.97M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$2.68M | (m) | (m) | (m) | (m) | -$2.48M | (m) | $1.67M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$2.85M | (m) | (m) | (m) | (m) | -$1.60M | (m) | $1.80M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$2.67M | (m) | (m) | (m) | (m) | -$1.57M | (m) | $798.00K | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$1.79M | (m) | (m) | (m) | (m) | -$1.73M | (m) | $689.00K | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$2.19M | (m) | (m) | (m) | (m) | -$958.00K | (m) | $492.00K | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$1.48M | (m) | (m) | (m) | (m) | -$688.00K | (m) | $333.00K | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$771.00K | (m) | (m) | (m) | (m) | -$675.00K | (m) | $225.00K | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$564.00K | (m) | (m) | (m) | (m) | -$544.00K | (m) | $112.00K | (m) | (m) |
| 2016-06-30 | Reported | (m) | -$707.00K | (m) | (m) | (m) | (m) | (m) | (m) | $139.00K | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$454.00K | (m) | (m) | (m) | (m) | (m) | (m) | $47.00K | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$338.00K | (m) | (m) | (m) | (m) | -$509.00K | (m) | $88.00K | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$549.00K | (m) | (m) | (m) | (m) | -$511.00K | (m) | $54.00K | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$452.00K | (m) | (m) | (m) | (m) | -$418.00K | (m) | $43.00K | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$619.00K | (m) | (m) | (m) | $0.00 | -$443.00K | (m) | $88.00K | (m) | (m) |
| 2014-06-30 | Reported | (m) | -$930.00K | (m) | (m) | (m) | $0.00 | -$410.00K | (m) | $72.00K | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$537.00K | (m) | (m) | (m) | $0.00 | -$378.00K | (m) | (m) | (m) | (m) |
| 2013-09-30 | Reported | (m) | -$51.00K | (m) | (m) | (m) | $0.00 | -$469.00K | (m) | (m) | (m) | (m) |
| 2013-06-30 | Reported | (m) | -$927.00K | (m) | (m) | (m) | $0.00 | -$889.00K | (m) | (m) | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$537.00K | (m) | (m) | (m) | $0.00 | -$407.00K | (m) | (m) | (m) | (m) |
| 2012-09-30 | Reported | (m) | -$630.00K | (m) | (m) | (m) | $0.00 | -$726.00K | (m) | (m) | (m) | (m) |
| 2012-06-30 | Reported | (m) | -$1.25M | (m) | (m) | (m) | $0.00 | -$1.13M | (m) | (m) | (m) | (m) |
| 2012-03-31 | Reported | (m) | -$616.00K | (m) | (m) | (m) | $0.00 | -$578.00K | (m) | (m) | (m) | (m) |
| 2011-09-30 | Reported | (m) | -$944.00K | (m) | (m) | (m) | $0.00 | -$636.00K | (m) | (m) | (m) | (m) |
| 2011-06-30 | Reported | (m) | -$572.00K | (m) | (m) | (m) | $0.00 | $1.77M | (m) | (m) | (m) | (m) |
| 2011-03-31 | Reported | (m) | -$1.02M | (m) | (m) | (m) | $0.00 | -$1.05M | (m) | (m) | (m) | (m) |
| 2010-09-30 | Reported | (m) | -$917.00K | (m) | (m) | (m) | (m) | -$550.00K | (m) | (m) | (m) | (m) |
| 2010-06-30 | Reported | (m) | -$2.50M | (m) | (m) | (m) | (m) | -$386.00K | (m) | (m) | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$6.28M | (m) | (m) | (m) | (m) | -$12.47M | (m) | $250.00K | (m) | $106.00K |
| 2024-12-31 | Reported | (m) | $2.57M | (m) | (m) | (m) | (m) | $26.98M | (m) | $307.00K | (m) | $365.00K |
| 2023-12-31 | Reported | (m) | -$12.77M | (m) | (m) | (m) | (m) | -$17.14M | $1.26M | $56.00K | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$22.59M | (m) | (m) | (m) | (m) | -$18.06M | $86.00K | $3.53M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$17.22M | (m) | (m) | (m) | (m) | -$14.22M | (m) | $4.98M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$17.89M | (m) | (m) | (m) | (m) | -$15.60M | (m) | $5.11M | (m) | $0.00 |
| 2019-12-31 | Reported | (m) | -$13.01M | (m) | (m) | (m) | (m) | -$9.06M | (m) | $5.61M | (m) | $0.00 |
| 2018-12-31 | Reported | (m) | -$10.41M | (m) | (m) | (m) | (m) | -$7.83M | (m) | $5.01M | (m) | $0.00 |
| 2017-12-31 | Reported | (m) | -$6.95M | (m) | (m) | (m) | (m) | -$3.64M | (m) | $1.94M | (m) | $0.00 |
| 2016-12-31 | Reported | (m) | -$2.87M | (m) | (m) | (m) | (m) | -$2.12M | (m) | $472.00K | (m) | $0.00 |
| 2015-12-31 | Reported | (m) | -$1.89M | (m) | (m) | (m) | (m) | (m) | (m) | $256.00K | (m) | $0.00 |
| 2014-12-31 | Reported | (m) | -$2.88M | (m) | (m) | (m) | (m) | -$1.70M | (m) | $357.00K | (m) | $0.00 |
| 2013-12-31 | Reported | (m) | -$1.93M | (m) | (m) | (m) | $0.00 | -$2.21M | (m) | $579.00K | (m) | $0.00 |
| 2012-12-31 | Reported | (m) | -$3.62M | (m) | (m) | (m) | $0.00 | -$2.99M | (m) | $2.08M | (m) | $0.00 |
| 2011-12-31 | Reported | (m) | -$3.44M | (m) | (m) | (m) | $0.00 | -$3.23M | (m) | $1.49M | (m) | (m) |
| 2010-12-31 | Reported | (m) | -$4.60M | (m) | (m) | (m) | (m) | -$1.93M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |